Daily Stock Analysis, FAZ, FATE THERAPEUTICS INC, priceseries

FATE THERAPEUTICS INC. Daily Stock Analysis
Stock Information
Open
30.30
Close
30.42
High
30.93
Low
30.10
Previous Close
30.09
Daily Price Gain
0.33
YTD High
70.84
YTD High Date
Jan 3, 2019
YTD Low
29.90
YTD Low Date
Nov 19, 2019
YTD Price Change
-36.55
YTD Gain
-54.58%
52 Week High
83.86
52 Week High Date
Dec 26, 2018
52 Week Low
29.90
52 Week Low Date
Nov 19, 2019
52 Week Price Change
-25.45
52 Week Gain
-45.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 2. 2018
52.03
Feb 14. 2018
55.05
8 Trading Days
5.80%
Link
LONG
Mar 21. 2018
51.51
Apr 4. 2018
56.20
9 Trading Days
9.09%
Link
LONG
Dec 4. 2018
54.99
Dec 27. 2018
70.24
15 Trading Days
27.74%
Link
Company Information
Stock Symbol
FAZ
Exchange
NASDAQ
Company URL
http://www.fatetherapeutics.com
Company Phone
858.875.1803
CEO
J. Scott Wolchko
Headquarters
California
Business Address
3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001434316
About

Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. Fate Therapeutics was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.